James Healy
James Healy's purchase track record
How the stock did after each of James Healy's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/27/2024 | BIOA | $12.00M | -73.8% | -81.8% | -2.7% |
| 7/1/2024 | RAPP | $1.08M | -19.5% | -27.3% | +7.9% |
| 6/10/2024 | RAPP | $9.50M | -24.9% | -21.6% | +12.9% |
| 1/30/2024 | AVBP | $8.00M | -24.9% | 0.0% | +10.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Natera Named to TIME Best Inventions, Gets PT Hikes. Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Guggenheim initiates coverage of Rapport Therapeutics, sets $65 target. Guggenheim began coverage of Rapport Therapeutics and assigned a price target of $65. The target sits above the company's 52‑week high of $52.93, indicating a positive outlook. The stock currently trades with a low RSI and near a strong support level, which may influence market reaction to the new estimate.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVBP Included in Whale Activity Among 10 Health Care Stocks. AVBP was listed among ten health‑care stocks that saw significant whale activity during today's trading session. The move indicates that large institutional investors are actively buying shares of the company. This activity could signal increased confidence in AVBP's prospects. The stock remains within its 52‑week range and near the midpoint of analyst target levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
Transaction History
| SPTX | ▼ Sell | Other | 804,379 | — | 5/4/2026 | View on chart |
| SPTX | ▼ Sell | Other | 1,927,159 | — | 5/4/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 142 | — | 4/25/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 114 | — | 1/31/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 153 | — | 10/25/2024 | View on chart |
| BIOA | ▼ Sell | Other | 1,638,236 | — | 9/27/2024 | View on chart |
| BIOA | ▲ Buy | Open Market | 588,888 | $10.6M | 9/27/2024 | View on chart |
| BIOA | ▲ Buy | Open Market | 26,497 | $477K | 9/27/2024 | View on chart |
| BIOA | ▲ Buy | Open Market | 18,353 | $330K | 9/27/2024 | View on chart |
| BIOA | ▲ Buy | Open Market | 21,814 | $393K | 9/27/2024 | View on chart |
| BIOA | ▲ Buy | Open Market | 11,113 | $200K | 9/27/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 177 | — | 7/26/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,538 | $82K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,565 | $86K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 4,544 | $114K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 2,559 | $67K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,799 | $88K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 4,878 | $122K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 2,748 | $72K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,630 | $84K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,657 | $89K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 4,661 | $117K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 2,625 | $68K | 7/1/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 3,828 | $93K | 7/1/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 2,964 | — | 6/28/2024 | View on chart |
| RAPP | ▼ Sell | Other | 1,392,738 | $0 | 6/10/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 470,589 | $8.0M | 6/10/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 18,641 | $317K | 6/10/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 17,861 | $304K | 6/10/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 26,278 | $447K | 6/10/2024 | View on chart |
| RAPP | ▲ Buy | Open Market | 25,455 | $433K | 6/10/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 210 | — | 4/26/2024 | View on chart |
| AVBP | ▼ Sell | Other | 1,252,308 | — | 1/30/2024 | View on chart |
| AVBP | ▲ Buy | Open Market | 444,444 | $8.0M | 1/30/2024 | View on chart |
| NTRA | ▲ Buy | Grant | 264 | $17K | 1/26/2024 | View on chart |
| NTRA | ▼ Sell | Open Market | 644,000 | $37.8M | 12/13/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 396 | $17K | 10/27/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 328 | $16K | 7/28/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 2,750 | — | 6/30/2023 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 3,534 | — | 5/25/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 285 | $16K | 4/14/2023 | View on chart |
| NTRA | ▲ Buy | Grant | 390 | $16K | 1/13/2023 | View on chart |
| NTRA | ▼ Sell | Open Market | 2,400 | $90K | 11/16/2022 | View on chart |
| NTRA | ▲ Buy | Grant | 344 | $16K | 10/14/2022 | View on chart |
| NTRA | ▲ Buy | Option Exercise | 1,307 | — | 5/25/2022 | View on chart |
| CHRS | ▼ Sell | Open Market | 286,076 | $4.6M | 9/29/2021 | View on chart |
| CHRS | ▼ Sell | Open Market | 48,329 | $830K | 9/28/2021 | View on chart |
| CHRS | ▼ Sell | Open Market | 100,150 | $1.8M | 9/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.